NA
AVXL icon

NewEdge Advisors’s Anavex Life Sciences AVXL Stock Holding History

NewEdge Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$95.5K Buy
36,890
+157
+0.4% +$465 ﹤0.01% 2962
2026
Q1 		$113K Buy
36,733
+8,502
+30% +$36.8K ﹤0.01% 2723
2025
Q4 		$101K Buy
28,231
+26,605
+1,636% +$163K ﹤0.01% 2760
2025
Q3 		$14.5K Hold
1,626
– – ﹤0.01% 3228
2025
Q2 		$15K Buy
+1,626
New +$13.9K ﹤0.01% 3048
2023
Q1 		– Sell
-140
Closed -$1.3K – 3466
2022
Q4 		$1.3K Buy
+140
New +$1.5K ﹤0.01% 2957

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NewEdge Advisors's AVXL Position: Q2 2026 in Review

NewEdge Advisors increased its Anavex Life Sciences (AVXL) stake by 0.43% in Q2 2026, buying an estimated $465 and bringing the position to 36,890 shares worth $95.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2962.

NewEdge Advisors first reported a position in AVXL in Q4 2022 and has held it in 6 quarters since. The position peaked at $113K in Q1 2026. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • NewEdge Advisors held 36,890 shares of Anavex Life Sciences worth $95.5K as of Q2 2026.
  • NewEdge Advisors bought 157 Anavex Life Sciences shares in Q2 2026, an estimated $465.
  • Anavex Life Sciences made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2962 holding.
  • NewEdge Advisors first reported a position in Anavex Life Sciences in Q4 2022 and has held it in 6 quarters since.
  • NewEdge Advisors's Anavex Life Sciences position peaked at $113K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.